QPPV.COM KNOWLEDGE ASSESSMENT

Crovalimab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Crovalimab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which scenario most strongly suggests a potential trigger for breakthrough haemolysis despite ongoing treatment?

A well-documented stable maintenance dose with no intercurrent illness A serious infection occurring around a delayed or missed dose A remote history of uncomplicated injection-site redness A normal haemoglobin concentration with no symptoms

Question 2 of 10 What is the most appropriate approach to a thrombosis reported during crovalimab treatment?

Automatically attribute it to crovalimab because the event occurred during exposure Assume effective complement inhibition makes thrombosis impossible Assess haemolysis, adherence, infection, prior thrombosis, anticoagulation and other PNH-related risks Exclude it from pharmacovigilance because thrombosis is part of the underlying disease

Question 3 of 10 Which case-processing practice most directly supports biological-product traceability?

Recording the exact product and batch when relevant Recording only the therapeutic indication Replacing the product name with the antibody target Omitting administration details once causality is assessed

Question 4 of 10 Which combination best describes crovalimab's principal pharmacological and engineering classifications?

A terminal-complement inhibitor and pH-dependent recycling monoclonal antibody An upstream complement activator and Fc-free antibody fragment A CD59 replacement protein and conventional small-molecule inhibitor A broad immunosuppressant and cytokine-release enhancer

Question 5 of 10 Which statement best explains why invasive meningococcal infection is a mechanism-based safety concern with crovalimab?

C5 inhibition increases bacterial growth by directly stimulating Neisseria metabolism Terminal complement contributes to defence against Neisseria, so effective C5 blockade creates predictable susceptibility Crovalimab causes universal neutropenia that specifically targets meningococci Meningococcal infection is expected only because subcutaneous injections damage the skin barrier

Question 6 of 10 Which follow-up detail is most important for interpreting a suspected switching-related immune-complex reaction?

The patient's unrelated childhood vaccination history The previous C5 inhibitor, its last dose date, the first crovalimab dose and reaction latency Only the patient's injection-site measurement Only whether the patient had anaemia before the PNH diagnosis

Question 7 of 10 Why is C5 considered an effective target for reducing intravascular haemolysis in PNH?

C5 blockade restores CD55 and CD59 expression on PNH erythrocytes C5 is the point at which cleavage generates both inflammatory C5a and the C5b precursor of the membrane attack complex C5 inhibition eliminates the abnormal haematopoietic clone C5 blockade prevents all upstream complement activation and all immune-mediated inflammation

Question 8 of 10 A patient receiving crovalimab remains anaemic, but LDH and urine haemoglobin are not elevated. What is the most appropriate interpretation?

The findings conclusively prove loss of C5 blockade The anaemia should be assessed for non-intravascular causes such as marrow failure, bleeding or extravascular haemolysis The patient must have developed meningococcal infection The result demonstrates that crovalimab has caused antibody-mediated destruction of erythrocytes

Question 9 of 10 Which patient group was specifically included in the authorised EU therapeutic context described in the article?

Adults and adolescents aged 12 years or older weighing at least 40 kg with PNH, including selected treatment-naive and stable prior C5-inhibitor patients All children with PNH regardless of age or body weight Only adults who have never received a complement inhibitor Patients with any autoimmune disease regardless of evidence of PNH

Question 10 of 10 Which information is most directly valuable when assessing suspected breakthrough intravascular haemolysis?

Only the patient's vaccination date LDH, bilirubin, haptoglobin, reticulocytes, haemoglobinuria and dosing chronology Only the site of the most recent injection Only the patient's age and sex

Crovalimab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Cookie Settings